This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

EPHESUS trial (thrombosis prophylaxis)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The EPHESUS trial aimed to determine whether the pentasaccharide fondaparinux was more effective than low-molecular-weight heparin at preventing deep venous thrombosis after elective hip replacement.

The multi-centre, double-blind trial enrolled 2309 consecutive patients, aged over 18 years, undergoing elective hip-replacement surgery. Patients were allocated to postoperative 2.5 mg s/c injections of fondaparinux vs. 40 mg s/c injections of enoxaparin daily.

Reference:

1) Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. (2002). Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359(9319):1715-20


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.